Asunaprevir
![]() |
- ₹0
- Product name: Asunaprevir
- CAS: 630420-16-5
- MF: C35H46ClN5O9S
- MW: 748.29
- EINECS:681-328-7
- MDL Number:MFCD27987900
- Synonyms:(1R,2S)-N-[(1,1-Dimethylethoxy)carbonyl]-3-methyl-L-valyl-(4R)-4-[(7-chloro-4-methoxy-1-isoquinolinyl)oxy]-L-prolyl-1-amino-N-(cyclopropylsulfonyl)-2-ethenylcyclopropanecarboxamide;Asunaprevir;BMS 650032;Asunaprevir (BMS-650032);BMS 650032/Asunaprevir;Asunaprevir API;tert-butyl N-[(2S)-1-[(2S,4R)-4-(7-chloro-4-methoxyisoquinolin-1-yl)oxy-2-[[(1R,2S)-1-(cyclopropylsulfonylcarbamoyl)-2-ethenylcyclopropyl]carbamoyl]pyrrolidin-1-yl]-3,3-dimethyl-1-oxobutan-2-yl]carbamate;BMS-650032; BMS 650032; BMS650032
Manufacturer | Product number | Product description | Packaging | Price | Updated | Buy |
---|
Properties
Melting point :149-150oC
Density :1.37
storage temp. :-20°C Freezer, Under inert atmosphere
solubility :DMSO (Slightly), Methanol (Slightly, Heated)
form :Solid
pka :4.49±0.40(Predicted)
color :White to Off-White
Density :1.37
storage temp. :-20°C Freezer, Under inert atmosphere
solubility :DMSO (Slightly), Methanol (Slightly, Heated)
form :Solid
pka :4.49±0.40(Predicted)
color :White to Off-White
Safety Information
Symbol(GHS): |
![]() |
|||||||||||||||||||||||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Signal word: | Warning | |||||||||||||||||||||||||||||||||||
Hazard statements: |
|
|||||||||||||||||||||||||||||||||||
Precautionary statements: |
|
Description
Sold under the trade name Sunvepra®, asunaprevir received approval in Japan as part of a combination treatment for the hepatitis C virus (HCV). Working in concert with daclatasvir (IX) (vide infra), asunaprevir is a unique treatment for HCV, as it is free from both interferon and ribavirin and is administered orally. This direct-acting anti-viral, which was developed by Bristol–Myers Squibb (BMS), works as an NS3/4A protease inhibitor, representing a valuable treatment option for patient populations who are unable to receive, or do not respond to, the standard course of treatment—peginterferon/ribavirin.More related product prices
630423-36-8Related product price
- 630423-36-8
₹7800